Summary of Phase 1 Zoldonrasib Data at AACR 2026 ( Abstract # CT021 ) ...

The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

A joint research group consisting of Saitama Medical University and Meiji Holdings Co., Ltd. today announced results from a ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

Leah Phillips, a Kentucky mom of three, said she was initially told her symptoms were due to a cold, allergies or anxiety ...